| OAB0403 | Pooled analysis of 4 international trials of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged >65 or older demonstrating safety and efficacy: Week 48 results | Oral abstract session with live Q&A | B25 |
| OAB0402 | Dolutegravir- versus low-dose Efavirenz-based regimen for the initial treatment of HIV-1 infection in Cameroon: Week 96 results of the ANRS 12313 ' NAMSAL trial | Oral abstract session with live Q&A | B30 |
| OAB0305 | Islatravir safety analysis through week 48 from a phase 2 trial in treatment naïve adults with HIV-1 infection | Oral abstract session with live Q&A | B66 |
| OAB0304 | Reducing ART to less than 3-ARV regimen linked to increased systemic inflammation | Oral abstract session with live Q&A | B32 |
| OAB0303 | Adherence and factors associated with virologic success in HIV-1 infected adults with tuberculosis receiving raltegravir or efavirenz in the ANRS 12300 Reflate TB2 trial | Oral abstract session with live Q&A | B30 |
| OAB0302 | Analysis of protocol defined virologic failure through week 48 from a phase 2 trial (P011) of islatravir and doravirine in treatment-naïve adults with HIV-1 infection | Oral abstract session with live Q&A | B30 |
| OAB0205 | Vesatolimod, a toll-like receptor 7 (TLR7) agonist, induces dose-dependent immune responses in HIV controllers | Oral abstract session with live Q&A | B40 |
| OAB0204 | A new tool for achieving the first goal of UNAIDS 90-90-90 targets - HIV self-testing with urine | Oral abstract session with live Q&A | B4 |
| OAB0203 | Effects of immune-check point inhibitors on anti-HIV specific immune responses and HIV-reservoir in people living with HIV (PLHIV) and cancer | Oral abstract session with live Q&A | B40 |
| OAB0202 | Late-onset opportunistic infections while on ART in Latin America | Oral abstract session with live Q&A | B11 |